NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
Clinical Trials
74 trialsNCT07284433 2026-03-12
QUADvance
AvenCell Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04416984 2026-03-04
ALPHA2
Allogene Therapeutics
Phase 1/2 Active not recruiting
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT04629729 2025-12-11
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
NCT03016377 2025-10-27
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT02251548 2025-10-24
iFCR
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02722668 2025-07-04
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01350258 2025-05-31
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Phase 1/2 Terminated
NCT06756321 2025-01-03
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
Affiliated Hospital of Nantong University
Phase EARLY_PHASE1 Recruiting
NCT03743246 2024-08-15
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Celgene
Phase 1/2 Terminated
NCT03919526 2023-12-08
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1 Completed
NCT00924170 2023-11-14
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04245722 2023-10-26
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
Phase 1 Terminated
NCT02280525 2023-06-07
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01410344 2022-12-08
BMT CTN 0903
Medical College of Wisconsin
Phase 2 Completed
NCT01807611 2022-10-31
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
St. Jude Children's Research Hospital
Phase 2 Completed
NCT05528887 2022-09-06
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase 1 Recruiting
NCT04214886 2022-08-15
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
Loyola University
Phase 1 Active not recruiting
NCT01119066 2022-08-05
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00924326 2022-01-12
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03594162 2021-12-03
Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch
UNC Lineberger Comprehensive Cancer Center
No longer available
NCT00759798 2021-09-05
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00378534 2021-06-16
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03885947 2021-05-24
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT02423915 2021-01-08
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00305682 2020-11-19
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00536978 2020-09-24
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00303719 2020-05-12
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01490723 2020-05-05
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00566696 2020-04-14
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01010217 2020-03-25
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00498316 2020-02-28
Cord Blood Expansion on Mesenchymal Stem Cells
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02274506 2020-01-22
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00048412 2020-01-18
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Baylor College of Medicine
Phase 1/2 Completed
NCT02145039 2019-12-26
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Phase NA Terminated
NCT02167958 2019-10-15
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
University of Pittsburgh
Phase 1 Completed
NCT01875237 2019-07-16
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00801931 2019-03-27
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Columbia University
Phase 1/2 Terminated
NCT01408563 2019-01-23
Reduced Intensity Double Umbilical Cord Blood Transplantation
Massachusetts General Hospital
Phase 2 Completed
NCT00074490 2018-12-31
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00860457 2018-11-21
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Georgetown University
Phase 2 Completed
NCT01342289 2018-10-17
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT01745913 2018-07-11
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Weill Medical College of Cornell University
Phase 2 Terminated
NCT01135329 2018-07-03
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00794820 2018-05-08
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01653717 2017-08-17
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02194374 2017-06-12
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 1 Withdrawn